Surgeon discovers his own cancer after using an ultrasound connected to an iPhone

Apple is focusing on using its mobile devices to improve health care. Being able to use one of the company’s mobile devices to make an accurate, but quick diagnosis is one of the most important possibilities to come from this. And a real life example of this has taken place with a portable ultrasound device that works with the iPhone. Called the Butterfly IQ, the medical accessory was used by a vascular surgeon to find a cancerous mass in his throat.

Doctor John Martin had been having an uncomfortable feeling in his throat when he decided to use the Butterfly IQ to see what was going …

Facebook censored a cartoon breast cancer awareness campaign

Facebook still has a thing or two to learn about what’s considered acceptable in your timeline. The social network is catching flak after it briefly took down an ad for Cancerfonden’s breast cancer awareness campaign that included cartoon representations of breasts — and very abstract ones at that (they were just pink circles).


The company has since restored the post and apologized, but only after Cancerfonden unsuccessfully tried using a ‘safe’ blurry image and posted an open letter that blasted Facebook’s stance. You’d need square breasts to make Facebook happy, the organization argued.

In apologizing for the move, Facebook said that it examines “millions” of ad images each week and sometimes bans them by mistake. There’s no denying that the internet giant has a lot on its plate, and that it would be difficult to completely avoid slip-ups.

However, this is just the latest in a string of incidents where Facebook has been overly aggressive with takedowns, only to backtrack after a public uproar. And this time, it can’t pin the removal on ambiguities in its existing policy — it acknowledged that the original image was fine in its mea culpa.

Clearly, the company has yet to reach that point where it can reliably tell the difference between potentially offensive content and something that’s merely testing boundaries.

Google Life Sciences teams up with Sanofi to take down diabetes

Google Life Sciences, the new Google Alphabet standalone division established several weeks ago, today entered into a partnership with Sanofi, a French pharmaceutical firm to expand its research into treatments for diabetes.


Sanofi and Google will pool their expertise in science and tech to work on more integrated ways to collect, analyze and understand information, and in doing so, hopefully make it easier for patients to better manage and lower the cost of the chronic disease.

Diabetes occurs when the pancreas cannot produce, or the body cannot adequately use, insulin. A hormone made by the pancreas, insulin lets glucose from food pass from the blood stream into the cells of the body to produce energy. The latest edition IDF Diabetes Atlas estimates that people living with diabetes will expand from 382 million to 592 million people by 2035.

The new collaboration centers on improving care and outcomes for patients suffering from type 1 and type 2 diabetes, pairing Sanofi’s treatments and devices with Google’s analytics, miniaturized electronics and low-power chips. The companies will work on developing new tools to improve patient care and develop new treatments that combine blood glucose and hemoglobin A1c level indicators, patient-centric information, medication routines and sensor devices.

Observers hope that the combined technology, sensors, analytics and digital applications will improve how blood sugars are managed, to deliver a better quality of life that lowers complications and reduces the costs and treatment barriers.

Google has a longstanding interest in diabetes, and has been working on other technologies, such as contact lenses that monitor glucose levels. Only two days after its Alphabet announcement, Google teamed up with healthcare firm Dexcom to build tiny blood glucose monitoring devices for diabetics.

Terms of the partnership between Google Life Sciences and Sanofi were not disclosed.